Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab maintenance in high-risk aggressive B-cell lymphoma
NCT03569696Phase 2Unknown
- Start
- Oct 2018
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in aggressive B-cell lymphoma. Status: unknown.
02
Drugs
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT03569696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569696.